Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Phase 2

Terminated

Conditions: Leukemia
Graft Versus Host Disease
Myelodysplastic Syndromes

First Posted Date: 2007-03-22

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00450983

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: sargramostim
Biological: anti-thymocyte globulin
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2007-03-16

Last Posted Date: 2017-05-30

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 71

Registration Number: NCT00448201

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Phase 1

Completed

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Lymphoma
Myelodysplastic Syndromes

Interventions: Biological: rabbit anti-thymocyte globulin (ATG)
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: fludarabine phosphate
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: methotrexate

First Posted Date: 2007-03-16

Last Posted Date: 2017-07-17

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 54

Registration Number: NCT00448357

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Bevacizumab

First Posted Date: 2007-03-15

Last Posted Date: 2015-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00448019

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Stage IV Melanoma
Recurrent Melanoma

First Posted Date: 2007-03-05

Last Posted Date: 2024-03-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00003552

Locations: 🇺🇸
National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States

Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Fludarabine
Drug: Melphalan
Procedure: Stem Cell Infusion

First Posted Date: 2007-01-31

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00429572

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: L-leucyl-L-leucine Methyl Ester (LLME)
Drug: Fludarabine
Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mesna
Biological: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Procedure: Hematopoietic stem cell transplantation (HSCT)

First Posted Date: 2007-01-31

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT00429416

Locations: 🇺🇸
Thomas Jefferson University', Philadelphia, Pennsylvania, United States

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Renal Cell Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00429026

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Cellular Therapy With Cord Blood Cells

Phase 2

Completed

Conditions: Multiple Myeloma
Leukemia
Lymphoma

Interventions: Drug: Fludarabine
Drug: Melphalan
Procedure: Umbilical Cord Blood
Drug: Rituximab
Other: Peripheral Blood Stem Cell Infusion

First Posted Date: 2007-01-29

Last Posted Date: 2012-05-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00427557

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Not Applicable

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Antithymocyte Globulin

First Posted Date: 2007-01-29

Last Posted Date: 2011-10-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00427336

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy